The Oxford University’s novel coronavirus vaccine candidate has shown promise in phase I/II human trials, according to peer-reviewed results of the study published The Lancet. Writing in the journal, the Oxford researchers said that their coronavirus vaccine — ChAdOx1 nCoV-19 — “showed an acceptable safety profile, and homologous boosting increased antibody responses”. This means that the Oxford coronavirus vaccine was shown to be safe and able to induce immune response against the virus in initial trials. The researchers added that the phase I/II results of the Oxford coronavirus vaccine “support largescale evaluation of this candidate vaccine”. The Oxford vaccine is already in phase III trials where it is being tested for the level of protection it affords against the novel coronavirus.